Epanova | AMRN Message Board Posts

Amarin Corporation plc

  AMRN website

  •  Registered Members of Investor Village:
    Please make sure you are signed in to your Investor Village account to enjoy the full benefits of our service and avoid the MediaPass paywall. If the MediaPass offer page is blocking you, click the light blue "No thanks, take me back" link on the middle right side of the form to get to our home page where you can sign in by entering your Investor Village User Name and Password. 

     MediaPass subscribers: Please make sure you are logged in to your MediaPass subscription to bypass the paywall. You can do this by clicking the light blue "Already have a MediaPass account? Login here" link on the middle left side of the subscription offer form and then entering the email address and password you used when you first signed up with MediaPass.  

    For assistance call 888-222-7309 or email admin@investorvillage.com

AMRN   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  4412 of 7349  at  6/20/2019 11:24:47 AM  by


 In response to msg 4409 by  sphericalkutz
view thread

Re: Epanova

  Thanks for the input. After reading my post again I wrote that example pretty badly - what I was trying to say is that there have been CVOTs that were criticized for not running long enough to trust the results - too many patients were enrolled in order to finish quickly and get a label update - but for the life of me I can't remember which one I'm thinking of - was a large trial of at least 18k patients that lasted ~3 yrs, may have only been 2.5 yrs.
ODYSSEY will likely be seen as both consistent with FOURIER, the earlier cardiovascular outcomes trial (CVOT) with Amgen’s evolocumab, and an incremental advance on that trial. Despite differences in patient populations and trial design, both trials resulted in a significant but modest 15% reduction in the primary endpoint. But the ODYSSEY mortality results and the subgroup results in patients with baseline LDL levels over 100 mg/dl appear to confer a decided advantage for ODYSSEY. The results will likely be seen as confirming the view that Amgen may have shot itself in the foot with FOURIER. In an attempt to gain a competitive advantage over Sanofi/Regeneron, Amgen increased the size of FOURIER to accumulate more endpoint events in as short a period of time as possible. As a result FOURIER was able to report results one year before ODYSSEY. But the downside is that FOURIER may have been unable to reflect the full benefit of evolocumab, since many events in the trial occurred before the beneficial effects of the drug had time to emerge. 

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 173
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
4413 Re: Epanova sphericalkutz 0 6/20/2019 11:49:13 AM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
Financial Market Data provided by